Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cyteir Therapeutics Inc
(NQ:
CYT
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
3.070 (100)
Ask (Size)
3.140 (105)
Prev. Close
3.020
Today's Range
N/A - N/A
52wk Range
2.730 - 3.190
Shares Outstanding
71,281,616
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
March 07, 2024
From
Cyteir Therapeutics
Via
Business Wire
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
October 12, 2023
From
Cyteir Therapeutics
Via
Business Wire
Performance
More News
Read More
Nasdaq Jumps 200 Points; Baudax Bio Shares Spike Higher
June 30, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
June 30, 2023
Via
Benzinga
Cyteir Therapeutics (NASDAQ: CYT) to Dissolve After Discontinuing Development of CYT-0851
June 30, 2023
Via
Spotlight Growth
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 30, 2023
Via
Benzinga
Crude Oil Rises Over 1%; Fed's Preferred Inflation Gauge Slows In May
June 30, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 30, 2023
Via
Benzinga
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
June 30, 2023
From
Cyteir Therapeutics
Via
Business Wire
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
June 03, 2023
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
May 10, 2023
From
Cyteir Therapeutics, Inc.
Via
Business Wire
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
March 23, 2023
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer
February 06, 2023
From
Cyteir Therapeutics
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
January 30, 2023
Via
Benzinga
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway
January 19, 2023
From
Cyteir Therapeutics
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023
January 20, 2023
Via
Benzinga
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights
November 07, 2022
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium
October 12, 2022
From
Cyteir Therapeutics
Via
Business Wire
5 Value Stocks In The Healthcare Sector
September 12, 2022
Via
Benzinga
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
August 31, 2022
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights
August 08, 2022
From
Cyteir Therapeutics
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
Via
Benzinga
Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 01, 2022
From
Cyteir Therapeutics
Via
Business Wire
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
July 27, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.